Association between Psychological, Biochemical and Personal Factors with the Inflammatory Marker High-Sensitive C Reactive Protein (Hs-CRP) in Mexican Healthy Population.

In the last decades, it has been shown that inflammatory processes play a role in the development of mental and physical problems; although some studies have researched the relationship between inflammation and psychological variables, the inclusion of biochemical variables as possible confounders has been limited. Therefore, the aim of this study was to determine whether psychological variables are associated with the inflammatory marker, highly sensitive CRP (hs-CRP), after controlling for personal and biochemical variables in the Mexican population. The study was performed at the University of Guadalajara facilities, during the second half of 2022. Healthy subjects were invited to participate in the study, which consisted of the measurement of personal, psychological, and biochemical variables. We included 172 participants, 92 (52.9%) of which were women; the median (range) of age of the whole sample was 22 (18-69) years old. In the bivariate analysis, significant positive correlations were observed between hs-CRP and body mass index (BMI) and waist/hip ratio (WHR) in both sexes, together with leukocytes, uric acid, low-density lipoprotein (LDL), triglycerides, and the liver enzymes gamma glutamyl transferase (GGT) and alkaline phosphatase (ALP). In the multivariate regression analysis of the global and men's samples, anxiety was positively associated with hs-CRP, while depression and positive relations with others were negatively associated with hs-CRP. In conclusion, psychological variables influence inflammation mainly in men, and anxiety was the main contributor; in addition, positive relation with others is a variable that should be further explored as a psychological protector of inflammation in both sexes.

Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial.

PURPOSE: The purpose of this study was to evaluate the clinical efficacy and safety of a novel ophthalmic solution of pazufloxacin on the ocular surface of patients with bacterial conjunctivitis after 7 days of intervention. METHODS: This is a phase 2, double-blind, controlled, multicenter, clinical trial of 300 subjects, randomized to either a 3 dosing regimen of pazufloxacin 0.6% ophthalmic solution (twice a day [BID], n = 90; 3 times a day [TID], n = 76; 4 times a day [QID], n = 68), moxifloxacin 0.3% TID (n = 82), or gatifloxacin 0.5% TID (n = 72). Follow-up was set on days 0, 3, and 7. Assessments of ocular signs were performed, both anterior and posterior segments. The primary outcome measures included conjunctival culture and clinical signs. Safety variables included adverse events (AEs), lisamine green, fluorescein ocular surface stains, and clinical signs of tolerability. RESULTS: After intervention, bacterial eradication was reported in all groups: pazufloxacin BID 79%, pazufloxacin TID 84%, pazufloxacin QID 84%, moxifloxacin 80%, and gatifloxacin 82%. There were no significant differences between treatments. Similar results were reported in clinical remission: pazufloxacin BID 89%, pazufloxacin TID 98%, pazufloxacin QID 92%, moxifloxacin 91%, and gatifloxacin 92% (P = 0.03 comparing pazufloxacin BID vs. TID). There were no differences between female and male responses. The AEs were not related to the interventions. CONCLUSIONS: A simplified dosing regimen was selected to follow the development of ophthalmic pazufloxacin based on its efficacy and safety profile. Pazufloxacin, 1 drop 3 times daily, showed similar rates of bacterial eradication and clinical remission compared with other fluoroquinolones.

Tres años de experiencia con el dispositivo intrauterino medicado con cobre (TCu-380A) en el Hospital Nacional Arzobispo Loayza / Three-year experience with the copper intrauterine device (TCu-380a) at Arzobispo Loayza National Hospital

Objetivo: Conocer la efectividad, aceptabilidad y causas de discontinuación de las usuarias del DIU que acuden a la consulta habitual. Lugar: Servicio de Planificación Familiar del HNAL. Material y Métodos: Durante el período de 1992 - 1994 se insertó 3706 DIU (TCu-380A) a mujeres sanas, 3167 en el período intergenésico, quienes previa información y examen ginecológico normal aceptaron este método; se programó controles mensuales, semestrales y anuales, para evaluar efectos secundarios y registrar causa y fecha de discontinuación. Se calculó las tasas acumuladas por año, totales y por razones de discontinuación, utilizando análisis de sobrevida, mediante el método de tabla de vida. Resultados: De un total de 3167 mujeres, 361 discontinuaron por diferentes razones, 1667 continúan activas al finalizar el estudio y 1139 no retornaron a su control; se encontró una tasa acumulada de discontinuación al 3er. año de 24,8 por 100 mujeres año uso. Las tasas brutas acumuladas por causas fueron: embarazo 1,10 (n igual 16), expulsión 10,19 (n igual 148), dolor 1,17 (n igual 17), sangrado vaginal anormal 1,99 (n igual 29), infección pélvica, 1,44(n igual 21), razones personales 8,73 (n igual 127), razones médicas 0,19 (n igual 3) y una tasa bruta acumulada de continuación de uso de 75,1. Conclusiones: La efectividad del DIU (TCu-380A) es similar a la publicada por otros investigadores; la pérdida de seguimiento es elevada, sobre todo en el primer año.

OBJETIVE. To know efficacy acceptability and causes of discontinuation in IUD users. SETING. Family Planning Service at ALAIH. MALTERIAL AND METHODS. During 1992-1994, 3706 TCu-380A IUDs were inserted to healthy patients, 3167 intergenesic, with prior information and normal gynecological exam; controls were monthly, semestral and annual to determine secondary effects and cause and date of discontinuation. Rates were estimated by year and total accumulation and reasons of discontinuation by life-table survival analysis. RESULTS. From 3167 women, 361 discontinued for different reasons, 1667 continued use and 1139 did not return to control. Discontinuation at three years was 24,8% per 100 woman-year use, because of pregnancy 1,10 (n=16), IUD expulsion 10,19 (n=148), pain 1,17 (n=17), abnormal vaginal bleeding 1,99 (n=29), pelvic infection 1,44 (n=21), personal reasons 8,73 (n=127), and medical reasons 0,19 (n=3); accumulated total conttinuity use rate was 75,1. CONCLUSIONS. Efficacy of TCu-380A IUD is similar to that reported by other investigators. Loss to follow-up is high, especially during the first year.